, Volume 232, Issue 19, pp 3607–3614 | Cite as

LSD enhances the emotional response to music

  • M. KaelenEmail author
  • F. S. Barrett
  • L. Roseman
  • R. Lorenz
  • N. Family
  • M. Bolstridge
  • H. V. Curran
  • A. Feilding
  • D. J. Nutt
  • R. L. Carhart-Harris
Original Investigation



There is renewed interest in the therapeutic potential of psychedelic drugs such as lysergic acid diethylamide (LSD). LSD was used extensively in the 1950s and 1960s as an adjunct in psychotherapy, reportedly enhancing emotionality. Music is an effective tool to evoke and study emotion and is considered an important element in psychedelic-assisted psychotherapy; however, the hypothesis that psychedelics enhance the emotional response to music has yet to be investigated in a modern placebo-controlled study.


The present study sought to test the hypothesis that music-evoked emotions are enhanced under LSD.


Ten healthy volunteers listened to five different tracks of instrumental music during each of two study days, a placebo day followed by an LSD day, separated by 5–7 days. Subjective ratings were completed after each music track and included a visual analogue scale (VAS) and the nine-item Geneva Emotional Music Scale (GEMS-9).


Results demonstrated that the emotional response to music is enhanced by LSD, especially the emotions “wonder”, “transcendence”, “power” and “tenderness”.


These findings reinforce the long-held assumption that psychedelics enhance music-evoked emotion, and provide tentative and indirect support for the notion that this effect can be harnessed in the context of psychedelic-assisted psychotherapy. Further research is required to test this link directly.


LSD Serotonin 2A receptor Psychotherapy Psychedelic Music Emotion 



This research received financial and intellectual support from the Beckley Foundation and was conducted as part of a wider Beckley-Imperial research programme. The report presents independent research carried out at the NIHR/Wellcome Trust Imperial Clinical Research Facility. Support for Dr. Barrett was provided by the National Institute on Drug Abuse, Grant T32DA07209. The authors would like to thank Matthew Wall and Nicola Kalk for their help in designing this study.

Supplementary material

213_2015_4014_MOESM1_ESM.docx (66 kb)
ESM 1 (DOCX 66.1 KB)


  1. Barrett FS, Grimm KJ, Robins RW, Wildschut T, Sedikides C, Janata P (2010) Music-evoked nostalgia: affect, memory, and personality. Emotion 10:390–403CrossRefPubMedGoogle Scholar
  2. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–71CrossRefPubMedGoogle Scholar
  3. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate—a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol 57:289–300Google Scholar
  4. Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PCR, Strassman RJ (2015) Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. doi: 10.1177/0269881114565144.
  5. Bonny HL, Pahnke WN (1972) The use of music in psychedelic (LSD) psychotherapy. J Music Ther 9:64–87CrossRefGoogle Scholar
  6. Busch AK, Johnson WC (1950) L.S.D. 25 as an aid in psychotherapy; preliminary report of a new drug. Dis Nerv Syst 11:241–3PubMedGoogle Scholar
  7. Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, Tyacke RJ, Leech R, Malizia AL, Murphey K, Hobden P, Evans J, Feilding A, Wise RG, Nutt DJ (2012) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A 109:2138–43PubMedCentralCrossRefPubMedGoogle Scholar
  8. Carhart-Harris RL, Kaelen M, Whalley MG, Bolstridge M, Feilding A, Nutt DJ (2014) LSD enhances suggestibility in healthy volunteers. Psychopharmacology 232(4):785–794CrossRefPubMedGoogle Scholar
  9. Cohen S (1970) Drugs of hallucination: the LSD story. Harper Collins, New YorkGoogle Scholar
  10. Eagle CT (1972) Music and LSD: an empirical study. J Music Ther IX:23–38CrossRefGoogle Scholar
  11. Garcia-Romeu A, Griffith RR, Johnson MW (2014) Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev 7:157–164CrossRefPubMedGoogle Scholar
  12. Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, Brenneisen R (2014a) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 202(7):513–20PubMedCentralCrossRefPubMedGoogle Scholar
  13. Gasser P, Kirchner K, Passie T (2014b) LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J Psychopharmacol 1:57–68Google Scholar
  14. Gaston ET, Eagle CT (1970) The function of music in LSD therapy for alcoholic patients. J Music Ther VII:3–19CrossRefGoogle Scholar
  15. Griffiths RR, Richards WA, McCann U, Jesse R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187:268–83, discussion 84-92 CrossRefPubMedGoogle Scholar
  16. Griffiths RR, Richards W, Johnson MW, McCann U, Jesse R (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 22:621–32PubMedCentralCrossRefPubMedGoogle Scholar
  17. Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R (2011) Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology 218:649–65PubMedCentralCrossRefPubMedGoogle Scholar
  18. Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL et al (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68:71–8CrossRefPubMedGoogle Scholar
  19. Grof S (1980) LSD psychotherapy. Hunter House Publishers, AlamedaGoogle Scholar
  20. Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX (2004) Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology 172(2):145–56CrossRefPubMedGoogle Scholar
  21. Johnson MW, Richards W, Griffiths R (2008) Human hallucinogen research: guidelines for safety. J Psychopharmacol 22:603–20PubMedCentralCrossRefPubMedGoogle Scholar
  22. Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR (2014) Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol 28:983–92CrossRefPubMedGoogle Scholar
  23. Juslin PN, Vastfjall D (2008) Emotional responses to music: the need to consider underlying mechanisms. Behav Brain Sci 31:559–75, discussion 75-621 CrossRefPubMedGoogle Scholar
  24. Koelsch S (2014) Brain correlates of music-evoked emotions. Nature reviews. Neuroscience 15:170–80PubMedGoogle Scholar
  25. Leuner HC (1983) Psycholytic therapy: hallucinogenics as an aid in psychodynamically oriented psychotherapy. In: Grinspoon J, Bakalar JB (eds) Psychedelic reflections. Human Science Press, Oxford, pp 177–92Google Scholar
  26. MacLean KA, Johnson MW, Griffiths RR (2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol 25:1453–61PubMedCentralCrossRefPubMedGoogle Scholar
  27. Maslow AH (1993) The farther reaches of human nature. Arkana, New YorkGoogle Scholar
  28. McCrae RR, Costa PT (1987) Validation of the five-factor model of personality across instruments and observers. J Pers Soc Psychol 52:81–90CrossRefPubMedGoogle Scholar
  29. Middlefell R (1967) The effects of LSD on body sway suggestibility in a group of hospital patients. Br J Psychiatry J Ment Sci 113:277–80CrossRefGoogle Scholar
  30. Moore KS (2013) A systematic review on the neural effects of music on emotion regulation: implications for music therapy practice. J Music Ther 50:198–242CrossRefPubMedGoogle Scholar
  31. Nettl B (1956) Music in primitive culture. Harvard University Press, CambridgeCrossRefGoogle Scholar
  32. Nichols DE (2004) Hallucinogens. Pharmacol Ther 101(2):131–81CrossRefPubMedGoogle Scholar
  33. Pahnke W (1963) Drugs and mysticism: an analysis of the relationship between psychedelic drugs and the mystical consciousness. A thesis completed for the degree of Doctor of Philosophy, Harvard University, Cambridge, MassGoogle Scholar
  34. Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A (2008) The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther 14(4):295–314CrossRefPubMedGoogle Scholar
  35. Peirce JW (2008) Generating stimuli for neuroscience using PsychoPy. Front Neuroinform 2:10PubMedCentralCrossRefPubMedGoogle Scholar
  36. Richards WA (2009) The rebirth of resarch with entheogens: lessons from the past and hypotheses for the future. J Transpers Psychol 41:139–50Google Scholar
  37. Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider, FX, Liechti, M. E. (2015) Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry. doi: 10.1016/j.biopsych.2014.11.015.
  38. Solursh LP, Rae JM (1966) LSD, suggestion and hypnosis. Int J Neuropsychiatry 2:60–4PubMedGoogle Scholar
  39. Studerus E, Gamma A, Kometer M, Vollenweider FX (2012) Prediction of psilocybin response in healthy volunteers. PLoS One 7(2), e30800PubMedCentralCrossRefPubMedGoogle Scholar
  40. Turek IS, Soskin RA, Kurland AA (1974) Methylenedioxyamphetamine (MDA)—subjective effects. J Psychoactive Drugs 6(1):7–14CrossRefGoogle Scholar
  41. Zentner M, Grandjean D, Scherer KR (2008) Emotions evoked by the sound of music: characterization, classification, and measurement. Emotion 8:494–521CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • M. Kaelen
    • 1
    Email author
  • F. S. Barrett
    • 2
  • L. Roseman
    • 1
    • 3
  • R. Lorenz
    • 3
  • N. Family
    • 4
  • M. Bolstridge
    • 1
  • H. V. Curran
    • 5
  • A. Feilding
    • 6
  • D. J. Nutt
    • 1
  • R. L. Carhart-Harris
    • 1
  1. 1.Centre for Neuropsychopharmacology, Division of Brain Sciences, Faculty of MedicineImperial College LondonLondonUK
  2. 2.Behavioral Pharmacology Research UnitJohns Hopkins School of MedicineBaltimoreUSA
  3. 3.The Computational, Cognitive and Clinical Neuroimaging Laboratory, The Centre for Neuroscience, Division of Brain SciencesImperial College LondonLondonUK
  4. 4.Psycholinguistics and Language Department, Faculty of Social SciencesUniversity of KaiserslauternKaiserslauternGermany
  5. 5.Clinical Psychopharmacology UnitUniversity College LondonLondonUK
  6. 6.The Beckley FoundationOxfordUK

Personalised recommendations